Takeda Oncology
Christopher Danes is a highly experienced professional in oncology, currently serving as the Scientific Director for Global Medical Affairs Oncology at Takeda Oncology since September 2010, where responsibilities include leading US and Global Lung Cancer initiatives. Prior to this role, Christopher Danes held various scientific roles, including postdoctoral fellowships at MD Anderson Cancer Center and Ordway Research Institute, focusing on cancer research and therapeutic targets. Educational background includes a Ph.D. in Cancer Biology from The University of Texas Health Science Center at Houston and a BSc in Biology from the University at Buffalo. Recognized for contributions to the field, Christopher Danes has secured significant research funding and presented findings at scientific conferences.
This person is not in any teams
This person is not in any offices
Takeda Oncology
21 followers
In 2008, Takeda Pharmaceutical Company Limited acquired Millennium Pharmaceuticals and the resulting company became exclusively focused on oncology. In 2014, Takeda Oncology was created to become the global headquarters for Takeda’s oncology specialty business unit, in Cambridge, Massachusetts, on the former Millennium Pharmaceuticals site. AtTakeda Oncology they endeavor to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients. This singular focus drives our aspirations to discover, develop and deliver breakthrough oncology therapies. By concentrating the power of leading scientific minds and the vast resources of a global pharmaceutical company, they are finding innovative ways to improve the treatment of cancer.They've built a portfolio of paradigm-changing therapies and a leading oncology pipeline. Though They've made great strides in our fight against cancer, they are determined to do more — to work harder and to reach higher. They continue to seek our aspirations with the same passion, agility and entrepreneurial spirit that has sustained our patient-centric culture and has made us the leaders in oncology that they are today.